Early endovascular grafts at Montefiore Hospital and their effect on vascular surgery  by Veith, Frank J. et al.
HISTORICAL VIGNETTES IN VASCULAR SURGERY
Norman M. Rich, MD, Section EditorFrom
U
C
C
So
of
Auth
Rep
10
The
to
m
0741
Cop
httpEarly endovascular grafts at Monteﬁore Hospital
and their effect on vascular surgery
Frank J. Veith, MD,a,b Jacob Cynamon, MD,c Claudio J. Schonholz, MD,d and Juan C. Parodi, MD,e
New York and Bronx, NY; Cleveland, Ohio; Charleston, SC; and Buenos Aires, Argentina
Vascular surgery is very fortunate. It recognized the transition from open surgery to endovascular procedures as treat-
ments for vascular disease early enough to adapt as a specialty. As a result, most vascular surgeons in North America
became competent with endovascular techniques, and the survival of the specialty was assured. The endovascular graft
program at Monteﬁore Hospital played a major role in vascular surgery’s early recognition of the importance of the
endovascular revolution. This article will review the history of this early endovascular graft program and how it inﬂuenced
the specialty. (J Vasc Surg 2014;59:547-50.)The Monteﬁore Division of Vascular Surgery had
a long-standing interest in aggressive efforts to save lower
limbs threatened by gangrene and critical limb ischemia.1,2
Many of the very distal reconstructive operations were
based on unusually ﬁne arteriography performed by our
interventional radiology colleagues.1 In addition, because
of the high cardiopulmonary risk of many of our limb
salvage patients and the multilevel nature of their arterial
occlusive disease, we embraced percutaneous transluminal
angioplasty and stenting of iliac and femoral arteries before
most other surgical groups.1,2 In all regards, our Monte-
ﬁore vascular surgeons were endovascular enthusiasts since
the mid-1970s. However, up until 1992, all endovascular
procedures except for intraoperative arteriography were
performed by the interventional radiologists at our institu-
tion with full concurrence and support of the vascular
surgeons.
In January 1987, at an International Interventional
Meeting organized by Dr Barry Katzen in Miami, one of
us (F.V.), who was attending because of interests in percu-
taneous transluminal angioplasty and stenting, heard a talk
on stents and the possible future use of prosthetic graft-
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://dx.doi.org/10.1016/j.jvs.2013.09.051(AAAs), a concept which had been proposed by Juan Par-
odi in 1976. This idea and the potential of endovascular
treatment of AAAs was a topic of much discussion among
the Monteﬁore vascular group, particularly as a way of
treating AAA patients with serious comorbidities. This
discussion intensiﬁed after Parodi and his colleagues per-
formed the ﬁrst clinical case on September 7, 1990, and
published their initial clinical experience with endovascular
aortic aneurysm repair (EVAR) in ﬁve patients.3
In August 1992, we were asked to care for a 76-year-
old man who had a painful 7.5-cm AAA in addition to
oxygen-dependent pulmonary insufﬁciency and severe
inoperable coronary artery disease with recurrent ventric-
ular arrhythmias. The patient was mentally alert and
wanted his AAA ﬁxed, but was deemed by all who evalu-
ated him to be a prohibitively high risk for an open AAA
repair. At that time, EVAR procedures had only been per-
formed in Argentina. Since we had been recently discussing
Parodi’s work, an endovascular graft repair was quickly
considered. The patient appeared to have favorable
anatomy for an EVAR procedure, with a long infrarenal
neck, a well-deﬁned distal neck, and large straight iliac
arteries.4 So one of us (F.V.) and another Monteﬁore
vascular surgeon, Dr Michael L. Marin, who played a major
role in the institution’s endovascular graft program, consid-
ered journeying to Buenos Aires to learn the procedure and
return to Monteﬁore to perform it.
Dr Parodi was called and indicated that he had no
immediate cases planned, but said that he might come to
New York City to present his work at our Annual Sympo-
sium, and at that time, he might help us perform the EVAR
procedure on our patient. Arteriograms and computed
tomographic scans were sent to Dr Parodi and then dis-
cussed with him by Dr Marin at an interventional cardi-
ology meeting in Milwaukee. At that meeting, it was
decided that the patient was a good candidate. However,
many logistic issues were left unresolved. One was getting547
Fig 1. A model similar to the endograft used in the ﬁrst U.S.
endovascular aneurysm repair (EVAR) patient. A Dacron graft was
hand-sewn to a large Palmaz-like balloon expandable stent. The
compressed stent was mounted on a minimally compliant balloon,
which was expanded in the abdominal aortic aneurysm (AAA) neck
to ﬁx the proximal end of the endograft to the normal-sized aortic
neck.
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Systems (JJIS) to use a large Palmaz stent since JJIS had
the rights to both Palmaz’s and Parodi’s patents. The
company was concerned that our use of a large Palmaz
stent without an Investigational Device Exemption would
impair the company’s ability to get Food and Drug Admin-
istration approval to implant Palmaz-Schatz stents in the
coronary arteries.
This issue was extensively discussed at a meeting
between Drs Veith and Marin and Marvin Woodall, Presi-
dent of JJIS, and Paul Marshall, Director of New Products
for JJIS. The meeting, which was sometimes heated and
lasted over 4 hours, took place at a restaurant in the Newark
Airport Marriott. After many negative statements from the
JJIS team, the issuewas ﬁnally resolved by having JJIS, which
would never let us use their large unapproved Palmaz stent
(P 5014), agree to let us use a similar one that was manufac-
tured in Argentina by a company owned by Carlos Sommer.
Next, funds for bringing the Argentinian team to the
U.S. had to be obtained. The team consisted of Juan Par-
odi, Claudio Schonholz, a talented interventional radiolo-
gist, and Hector Barone, an engineer who made and
assembled the various components of the delivery system
and stent graft. Funds for travel and hotel expenses for
the team for their stay in New York were obtained from
a grant from the James Hilton Manning and Emma Austin
Manning Foundation.
Our digital C-arm ﬂuoroscope to be used in the oper-
ating room for the procedure was one that had been dis-
carded by an interventional cardiology animal laboratory.
When Drs Parodi and Schonholz saw the primitive nature
of this instrument, they hesitated to perform the proce-
dure, but were convinced to do so because of their previous
commitment and the patient’s dire condition.
After obtaining institutional review board approval and
with the informed consent of the patient and his wife, his
EVAR procedure was performed under local anesthesia
on November 22, 1992. A 22-mm knitted Dacron graft
was sewn to a large balloon-expandable (Palmaz-like) stent
(Fig 1). The endograft, within a large sheath,3,4 was guided
into position ﬂuoroscopically so that the single proximal
stent was mostly within the 2.5-cm non-aneurysmal neck
of the AAA. The sheath was retracted and the stent
deployed by inﬂation of the balloon on which it was
mounted.4 No distal stent was employed. Despite that,
aneurysm exclusion was demonstrated by intraoperative
angiography. The prominent AAA pulse was markedly
reduced, and the patient’s pain was totally relieved. The
next morning, the patient had eaten a full breakfast and
was sitting up in a chair reading a magazine. He looked
far better than any other open AAA repair patient we had
ever seen. Postoperative computed tomographic scans
and ultrasonography conﬁrmed exclusion of the aneurysm
lumen.4 The patient was discharged 4 days after his proce-
dure, had no abdominal pain, and did well until he died
from his cardiac and rhythm problems 9 months later.
This ﬁrst U.S. EVAR had a profound effect on not only
the Monteﬁore Vascular Surgery Division but also vascularsurgery in the U.S. and around the world. The Monteﬁore
vascular surgeons, in collaboration with our interventional
radiologists and Argentinian colleagues, embarked on
a program of endovascular grafting for the treatment of
aneurysms, traumatic arterial lesions, and aorto-iliac and
femoral occlusive disease. We used modiﬁcations of Parodi’s
surgeon-made stent grafts or endografts, which consisted of
Fig 2. Early surgeon-made stent grafts based on Parodi’s concepts. Top left, An occlusion device consisting of
a Palmaz stent covered by a polytetraﬂuoroethylene (PTFE) graft closed at one end by ligatures. This was used for
occluding the common iliac artery opposite to an aortofemoral or aortoiliac endograft in an abdominal aortic aneurysm
(AAA) repair.5,8 Top right, A covered stent fabricated by hand-sewing a PTFE graft to a balloon-expandable Palmaz
stent, used for treating arterial injuries (eg, of the subclavian artery).7 Bottom, A PTFE graft with a Palmaz stent at
either end, used for some long iliac or popliteal aneurysms.10
Fig 3. Schematic conﬁguration of a unilateral aortofemoral
endograft used for treating complex and ruptured abdominal aortic
aneurysms (AAAs). Note the large Palmaz stent (p) is partly covered
(m) and partly uncovered. The open portion of the stent covers the
renal arteries (r) for secure ﬁxation. An endovascular anastomosis
(e) ﬁxes the distal end of the endograft within the common femoral
artery. The endograft is dilated (not shown) to entirely ﬁll the
lumen of the femoral and external iliac artery. When a common iliac
aneurysm is present, the ipsilateral hypogastric artery is occluded by
coils (c). The contralateral common iliac artery is occluded by
a covered stent (o) closed at one end by ligatures (s). The procedure
is completed by performing a femorofemoral bypass (f).5,8
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grafts with various sized Palmaz stents sewn to them
(Fig 2). The stent components of these endografts were
mounted on balloon catheters, compressed within a variety
of simple hollow tubes or sheaths, then inserted over previ-
ously placed guidewires and guided into position under ﬂuo-
roscopic control. Once in place, the sheaths or insertion
tubes were retracted and the stents deployed by balloon
inﬂation. Sometimes, the distal end of these grafts were ﬁxed
with a second stent. More often, the distal end of the endog-
raft was ﬁxed within the host artery with an endoluminal
hand-sewn suture anastomosis (Fig 3).5-7
We generally used these endografts in patients for
whom no other standard endovascular or open surgical
treatment option was available because of local or systemic
risk factors. These included high-risk AAAs, ruptured
AAAs, aneurysms in other locations difﬁcult to reach by
open exposures, very difﬁcult limb salvage patients usually
after multiple previous failures, and difﬁcult traumatic arte-
rial injuries like subclavian disruptions and arteriovenous
ﬁstulas.5-10 Even in these challenging circumstances, these
primitive surgeon-made endografts proved to be surpris-
ingly successful. The procedures proved to be easier and
less stressful on the patients undergoing them than we
had anticipated, even though our endovascular skills were
still not advanced.5-10
Because of the relative prominence of our Monteﬁore
vascular group, we were asked to speak on these early
endograft experiences quite often. Surprisingly, although
we ourselves remained skeptical in our presentations, others
hearing them were even more dubious about our results.
Indeed, we were often greeted with disbelief, and the
opinion of some was that, even if these procedures worked
sometimes, vascular surgeons should not be doing them.
Our attitude was just the opposite. We were convinced
that vascular treatment was undergoing a revolution: the
endo-revolution. We further believed that, if vascular
surgeons did not recognize that this was happening and
embrace endovascular skills and techniques, they would
rapidly be replaced by interventionalists in cardiology and
radiology, and vascular surgery would become extinct as
a specialty.11,12
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1996 to be President of two important vascular societies.
The theme of the Presidential Addresses before these
two societies was that vascular surgeons must recognize
the importance of this endovascular revolution and
embrace it. Considerable resistance to this was present, at
ﬁrst. Now, however, it is almost universally recognized,
and endovascular procedures make up the majority of
many vascular surgical practices. Interestingly, even the
predictions of an endovascular enthusiast of the late
1990s12 proved to be short of the mark. With the remark-
able creativity of all vascular specialists, it is now likely that
more than 90% of the open operations vascular surgeons
performed in the mid-1980s will be replaced by endovascu-
lar procedures. Even the small proportion of remaining
open operations will probably be made simpler or better
by using endovascular techniques for a portion of the
procedure.13
What happened at Monteﬁore in November 1992
certainly led to an epiphany for our entire vascular group
about the nature of vascular treatment in the future. In
subsequent years, that epiphany has fortunately spread to
the rest of vascular surgery, albeit sometimes slowly. We
believe that early recognition and adoption of endovascular
treatments by vascular surgeons everywhere will contribute
greatly to the survival and prosperity of the specialty.
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